Business Associate Agreement Janssen
Arrowhead is also eligible for milestone payments of up to $1.6 billion for the ARO-HBV licensing agreement and for options and milestone payments of nearly $1.9 billion under the second agreement. Janssen Pharmaceuticals has signed a licensing and cooperation agreement with Arrowhead Pharmaceuticals for the development and commercialization of a new therapeutic candidate, ARO-HBV. In addition, the companies entered into a separate cooperation and research options agreement, which included up to three additional RNAi therapeutic drugs against new targets chosen by Janssen. † Independent co-payment foundations have their own eligibility rules. We have no control over these independent foundations and we can only refer your patients to a foundation that supports their disease. We do not support a particular foundation. The basics of this list are not the only ones that might be able to help your patients. Transactions, subject to approval by the Hart-Scott-Rodino Antitrust Improvements Act, are expected to close in the fourth quarter of this year. ARO-HBV is a subcesseonderant candidate for ribonucleic acid (RNAi) that is developed to treat a chronic viral hepatitis B infection. Patients can also create their own Janssen CarePath account, where they can sign up for the Janssen CarePath Savings Program, learn more about their insurance coverage for DARZALEX® and sign up for personalized treatment reminders.
Encourage your patients to sign up for MyJanssenCarePath.com today. Let your legitimate patients start today. Visit the CarePath Provider Portal janssen to create an account and you can: The company can also receive staggered royalties for product sales. Call a CarePath Janssen Coordinator at 877-CarePath (877-227-3728) Mo-Fr From 8am to 8pm For more information, please contact Janssen CarePath Carordin Janssen CarePath is your only source of access, accessibility and assistance for your patients. Our dedicated Care Coordinator team supports the Janssen medications you prescribe. We can help you and your patients get the resources you need. Janssen CarePath helps verify your patients` insurance coverage, provides reimbursement information, helps find financial support for eligible patients and provides ongoing assistance to help patients start and stay on DARZALEX as planned®. JanssenPrescriptionAssistance.com provides information on affordable programs that may be available. A full list of accessibility programs can be accessed at JanssenPrescriptionAssistance.com/Darzalex. Sign up or sign up for the JanssenCarePathPortal.com Access Provider Portal “Working with Arrowhead`s talented team and its RNAi therapy candidates contributes to the strength of our hepatitis B portfolio and greatly increases our confidence that we can achieve our goal.” You can now submit an additional survey on the portal. Looking for a detailed overview of DARZALEX® refund and access? .
As part of the agreement, Arrowhead will use its TRiM platform and achieve the discovery, optimization and preclinical development of clinical candidates for selected targets. . For more information on these programs, please contact Janssen CarePath at 877-CarePath (877-227-3728), Monday to Friday, 8am-8pm ET, and speak to a CarePath Janssen Coordinator. If your patient has occupational or private health insurance, use this template for the medical necessity letter to request prior authorization for DARZALEX® treatment.